Friday, 19 Oct 2018

You are here

Good News from ACR17 - Gout

The following is a collection of gout-specific mentions culled from RheumNow's coverage of the Annual ACR 2017 meeting in San Diego.

Visit our RheumNow annual meeting site to read our gout content - http://acr17.rheumnow.com/category/gout-crystal/

Specific items:

  • Treatment of hyperuricemia to prevent incident dementia? Some data suggests this. Abstract #2076
  • PossibleGout and OA connection? Human cartilage increases amount and size of MSU crystals. Abstract #2896 http://ow.ly/ABLg30fM2gw
  • Low Uric acid may raise the risk of dementia. Abstract #2080
  • Lower coffee consumption is associated with gout!  Abstract #2066
  • Allopurinol and Febuxostat in lowes the risk of Dementia. Yes you read that right! Jas Singh et al. Abstract #2076
  • Both generic and environmental factors influence the fractional excretion of uric acid Abstract #2061
  • Hyperuricemia is associated with more rapid knee osteoarthritis progression. A&R 2017
  • Tollerizing pegloticase regimen decreases infusion reactions in the TRIPLE study Abstract #1141
  • Gout is under treated people… need to get better  Abstract #1121
  • If you have gout and type II diabetes you have worse gout. More tophi and erosions. Abstract #1118
  • Uncontrolled gout is associated with more heart failure so treat gout effectively. Abstract #1119
  • Risk for CV events lower with the new start probenecid (rather than allopurinol) for older >65 yo patients Abstract #159
  • Dr. Daniel Solomon YR in Review – the DASH diet decrease gout risk https://doi.org/10.1136/bmj.j1794 
  • Diuretics don’t seem to impact hugely on gout treatment objectives in this study Abstract #1129
  • Patients aren’t getting to urate target in gout when treated with allopurinol. Are we using enough? Abstract #166
  • Do we need to change the label ‘gout’ ?!?!? Has negative stereotypes  Abstract #1107
  • Patients with gout have their XOI stopped when they present with AKI. Evidence free zone and makes gout Rx harder. Abstract #1116
  • Gout patients more likely to achieve sUA goal< 6 mg/dL if managed by a rheumatologist. Go team Rheum! Abstract #166
  • Pre-Rx with methylprednisolone superior to HC as prophylaxis for pegloticase w/ greater drug survival  Abstract #213 https://buff.ly/2hKNl3y
  • Double contour sign - earliest sign of uric acid deposition obs in asymptomatic gout pts. Abstract #250 http://ow.ly/YZtb30fDVzZ
  • US of MTP1, distal patellar/triceps tendons, talar + femoral cartilage for MSU in possible gout Abstract #249
  • FORTUNE1: stepwise  Uloric dose comparable to colchicine+Uloric in flare prevention during introductory Rx 
  • Cankinumab reduces CV events, decreases risk of gout & malignancy. Higher infection risk  #YearInReview
  • “Gout patients can have septic arthritis and sickle cell pts can also have gout. Keep this in mind during your nex sickle cell crisis differential diagnoses.”  – J Cush, MD (Rheumatology Roundup). 

Gout Videos

Dr. Jack Cush: When Asymptomatic Hyperuricemia Should Be Treated 

 

Dr. Arthur Kavanaugh: Gout, OA Posters

 

Dr. Ken Saag: Update on Gout Therapy

 

Dr. Janet Pope: Gout Gamechangers 

Disclosures: 
The author has received research/grant financial support on this subject
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Nurse Led Gout Management Highly Effective

UK researchers have shown that nurse-led gout management, using a treat-to-target urate-lowering strategy, is efficacious and cost-effective compared with usual physicain care. The results are published in the recent Lancet edition.

Worldwide, gout management is suboptimal. In the UK only 40% of gout patients receive urate-lowering therapy, and fewer ever achieve a target serum urate (< 6mg/d) concentration.

It's the Genes, Not the Diet that Raises Urate

Researchers from New Zealand find that in contrast with genetic contributions, diet explains very little variation in serum urate levels in the general population.

Allopurinol Shown to be Renal Protective

Neogi and colleagues have shown that standard doses of allopurinol (300 mg/day) were associated with a 13% lower risk of renal function deterioration in chronic gout patients - thus, allopurinol does not appear to impair renal function over time.

Quarterly Canakinumab Reduces Gout Risk Without Affecting Uric Acid

The Annals of Internal Medicine reports that interleukin-1 (IL-1) inhibitor treatment is associated with a reduced risk of gout attacks - such are the findings of an anlysis of the CANTOS study previously reported at the Annual ACR 2017 meeting in Washington, DC. 

Usual Allopurinol Doses Insufficient in CKD Patients

Uric acid (sUA) control may be a challenge in patients with chronic kidney disease (CKD). A cohort study shows that conventional dosing recommendations for allopurinol are unlikely to reach target serum sUA goals.